Bvf Has Decreased Its Oncomed Pharmaceuticals (OMED) Position; Menora Mivtachim Holdings LTD Has Increased By $7.75 Million Its Applied Matls (AMAT) Holding

April 22, 2018 - By Linda Rogers

Applied Materials, Inc. (NASDAQ:AMAT) Logo

Menora Mivtachim Holdings Ltd increased Applied Matls Inc (AMAT) stake by 40.26% reported in 2017Q4 SEC filing. Menora Mivtachim Holdings Ltd acquired 151,960 shares as Applied Matls Inc (AMAT)’s stock rose 6.49%. The Menora Mivtachim Holdings Ltd holds 529,410 shares with $27.06 million value, up from 377,450 last quarter. Applied Matls Inc now has $53.68B valuation. The stock decreased 0.20% or $0.1 during the last trading session, reaching $51.09. About 14.54 million shares traded. Applied Materials, Inc. (NASDAQ:AMAT) has risen 42.67% since April 22, 2017 and is uptrending. It has outperformed by 31.12% the S&P500.

Bvf Inc decreased Oncomed Pharmaceuticals Inc (OMED) stake by 2.93% reported in 2017Q4 SEC filing. Bvf Inc sold 129,000 shares as Oncomed Pharmaceuticals Inc (OMED)’s stock declined 11.20%. The Bvf Inc holds 4.27M shares with $17.51 million value, down from 4.40 million last quarter. Oncomed Pharmaceuticals Inc now has $120.90M valuation. The stock increased 2.60% or $0.08 during the last trading session, reaching $3.16. About 94,784 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 22, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on May, 14. They expect $-0.24 EPS, up 60.66% or $0.37 from last year’s $-0.61 per share. After $0.25 actual EPS reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -196.00% negative EPS growth.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, October 6 by SunTrust. H.C. Wainwright initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Thursday, September 22 with “Buy” rating. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Market Perform” rating given on Tuesday, April 11 by BMO Capital Markets. H.C. Wainwright maintained it with “Hold” rating and $3.0 target in Friday, March 9 report. The firm has “Hold” rating given on Thursday, March 8 by SunTrust. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Buy” rating given on Wednesday, August 10 by Jefferies. Mizuho maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Tuesday, January 26. Mizuho has “Buy” rating and $15 target. On Monday, January 25 the stock rating was downgraded by Leerink Swann to “Mkt Perform”. As per Friday, December 4, the company rating was initiated by Wells Fargo. SunTrust initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Tuesday, December 20. SunTrust has “Buy” rating and $16 target.

Investors sentiment increased to 1.62 in Q4 2017. Its up 0.91, from 0.71 in 2017Q3. It is positive, as 3 investors sold OMED shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Perceptive Ltd Liability invested 0.36% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Northern accumulated 59,017 shares. Alyeska Invest LP owns 0.02% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 521,883 shares. Axa holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 131,785 shares. Prtnrs Ltd Llc reported 59,100 shares or 0.01% of all its holdings. Moreover, Primecap Mngmt Ca has 0.02% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 5.57M shares. First Eagle Management Limited Liability Company reported 0% stake. Tudor Inv Et Al has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Blackrock Inc reported 0% stake. Citigroup Incorporated has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Art Advsrs Limited Co owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 27,052 shares. 38,000 were reported by Nj State Employees Deferred Compensation Plan. Moreover, Hodges Capital has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). State Bank Of Montreal Can stated it has 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Barclays Public Limited Co accumulated 0% or 29,660 shares.

Menora Mivtachim Holdings Ltd decreased Paypal Hldgs Inc stake by 96,725 shares to 391,150 valued at $28.80 million in 2017Q4. It also reduced Nice Ltd (NASDAQ:NICE) stake by 40,926 shares and now owns 268,135 shares. Check Point Software Tech Lt (NASDAQ:CHKP) was reduced too.

Investors sentiment decreased to 0.86 in 2017 Q4. Its down 0.20, from 1.06 in 2017Q3. It dropped, as 52 investors sold AMAT shares while 367 reduced holdings. 113 funds opened positions while 249 raised stakes. 797.20 million shares or 1.72% less from 811.15 million shares in 2017Q3 were reported. Egerton Capital (Uk) Limited Liability Partnership stated it has 15.49 million shares. National Pension owns 961,508 shares. Fagan invested in 34,445 shares or 0.71% of the stock. Murphy Pohlad Asset Lc reported 15,350 shares. Caprock Group Inc reported 8,169 shares. Parnassus Invests Ca holds 0.02% or 100,000 shares in its portfolio. Meiji Yasuda Life reported 12,290 shares or 0.09% of all its holdings. Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys stated it has 95,395 shares. Oakworth invested 0.02% of its portfolio in Applied Materials, Inc. (NASDAQ:AMAT). Grassi Inv Mngmt owns 2.49% invested in Applied Materials, Inc. (NASDAQ:AMAT) for 300,519 shares. Hl Fincl Ltd Liability stated it has 92,012 shares or 0.09% of all its holdings. Barclays Public Lc accumulated 2.04 million shares or 0.09% of the stock. Virtus Investment Advisers invested 0.58% in Applied Materials, Inc. (NASDAQ:AMAT). Advantus Mgmt Incorporated owns 0.14% invested in Applied Materials, Inc. (NASDAQ:AMAT) for 109,636 shares. Raymond James Advisors invested in 0.03% or 92,383 shares.

Among 28 analysts covering Applied Materials Inc. (NASDAQ:AMAT), 27 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Applied Materials Inc. had 120 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, January 30 by Stifel Nicolaus. RBC Capital Markets maintained Applied Materials, Inc. (NASDAQ:AMAT) rating on Thursday, February 16. RBC Capital Markets has “Sector Perform” rating and $35 target. The rating was maintained by Cowen & Co on Wednesday, November 11 with “Outperform”. B. Riley & Co maintained the stock with “Buy” rating in Monday, August 14 report. The firm has “Sell” rating by Zacks given on Thursday, August 13. The stock of Applied Materials, Inc. (NASDAQ:AMAT) has “Underperform” rating given on Monday, October 5 by RBC Capital Markets. As per Friday, August 18, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Nomura with “Buy” on Friday, August 18. The stock of Applied Materials, Inc. (NASDAQ:AMAT) earned “Hold” rating by Nomura on Friday, August 14. UBS upgraded the shares of AMAT in report on Thursday, April 14 to “Buy” rating.

Since December 29, 2017, it had 0 buys, and 4 sales for $10.41 million activity. 125,125 Applied Materials, Inc. (NASDAQ:AMAT) shares with value of $6.44 million were sold by Salehpour Ali. Iannotti Thomas J also sold $922,050 worth of Applied Materials, Inc. (NASDAQ:AMAT) shares. Nalamasu Omkaram sold $2.83 million worth of stock. $214,680 worth of Applied Materials, Inc. (NASDAQ:AMAT) was sold by Forrest Stephen R.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: